» Articles » PMID: 10385508

Urokinase Receptor (uPAR, CD87) is a Platelet Receptor Important for Kinetics and TNF-induced Endothelial Adhesion in Mice

Overview
Journal Circulation
Date 1999 Jun 29
PMID 10385508
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Urokinase plasminogen activator receptor (uPAR, CD87) is a widely distributed 55-kD, glycoprotein I-anchored surface receptor. On binding of its ligand uPA, it is known to increase leukocyte adhesion and traffic. Using genetically deficient mice, we explored the role of uPAR in platelet kinetics and TNF-induced platelet consumption.

Methods And Results: Anti-uPAR antibody stained platelets from normal (+/+) but not from uPAR-/- mice, as seen by fluorescence-activated cell sorter analysis. 51Cr-labeled platelets from uPAR-/- donors survived longer than those from +/+ donors when injected into a +/+ recipient. Intratracheal TNF injection induced thrombocytopenia and a platelet pulmonary localization, pronounced in +/+ but absent in uPAR-/- mice. Aprotinin, a plasmin inhibitor, decreased TNF-induced thrombocytopenia. TNF injection markedly reduced the survival and increased the pulmonary localization of 51Cr-labeled platelets from +/+ but not from uPAR-/- donors, indicating that it is the platelet uPAR that is critical for their response to TNF. As seen by electron microscopy, TNF injection increased the number of platelets and polymorphonuclear neutrophils (PMNs) in the alveolar capillaries of +/+ mice, whereas in uPAR-/- mice, platelet trapping was insignificant and PMN trapping was slightly reduced. Platelets within alveolar capillaries of TNF-injected mice were activated, as judged from their shape, and this was evident in +/+ but not in uPAR-/- mice.

Conclusions: These results demonstrate for the first time the critical role of platelet uPAR for kinetics as well as for activation and endothelium adhesion associated with inflammation.

Citing Articles

Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors.

Rossmeisl J, King J, Robertson J, Weger-Lucarelli J, Elankumaran S Cancers (Basel). 2024; 16(3).

PMID: 38339315 PMC: 10854777. DOI: 10.3390/cancers16030564.


The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.

Di Costanzo A, Indolfi C, Sorrentino S, Esposito G, Spaccarotella C Int J Mol Sci. 2023; 24(14).

PMID: 37511498 PMC: 10380733. DOI: 10.3390/ijms241411739.


suPAR to Risk-Stratify Patients With Malaria.

Stefanova V, Crowley V, Weckman A, Kain K Front Immunol. 2022; 13:931321.

PMID: 35757694 PMC: 9226448. DOI: 10.3389/fimmu.2022.931321.


Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications.

Napolitano F, Montuori N Int J Mol Sci. 2022; 23(11).

PMID: 35682744 PMC: 9181697. DOI: 10.3390/ijms23116065.


Exposure of plasminogen and a novel plasminogen receptor, Plg-RKT, on activated human and murine platelets.

Whyte C, Morrow G, Baik N, Booth N, Jalal M, Parmer R Blood. 2020; 137(2):248-257.

PMID: 32842150 PMC: 7820873. DOI: 10.1182/blood.2020007263.